Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical executive Mark Brosius, EVP & Chief Manufacturing and Supply Chain, reported small open-market sales of company common stock. He sold 25 shares at $414.13 on June 12, 2026 and 23 shares at $412.16 on June 11, 2026, totaling 48 shares. After these transactions, he directly holds 1,406 shares of Intuitive Surgical common stock. The trades were executed under a pre-arranged Rule 10b5-1 trading plan that is stated to expire on February 14, 2027, indicating the timing was set in advance.
Intuitive Surgical EVP & Chief Manufacturing and Supply Chain officer Mark Brosius reported small open-market sales of company Common Stock. Across three days, he sold a total of 69 shares at prices between $420.12 and $424.14 per share.
After these transactions, Brosius directly holds 1,454 shares of Intuitive Surgical Common Stock. The filing notes that the trades were executed under a Trading Plan that complies with SEC Rule 10b5-1 and is scheduled to expire on February 14, 2027.
INTUITIVE SURGICAL INC executive Gary Loeb reported an open-market sale of 400 shares of Common Stock. The shares were sold at a price of $424.14 per share. After this transaction, he directly holds 5,720 shares. The sale was executed under a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and is scheduled to expire on January 29, 2027, indicating the timing was set in advance rather than being a discretionary trade.
ISRG notice of a proposed resale: 400 shares of Common stock (reported as Restricted Stock Units) are shown on a Form 144. The filing records a 10b5-1 sale by Gary Loeb of 400 shares on 05/11/2026 for $178,780.00.
INTUITIVE SURGICAL INC CEO David J. Rosa reported routine equity compensation activity involving restricted stock units (RSUs). On June 10, 2026, 1,358 RSUs granted on June 10, 2023 vested and converted into the same number of common shares on a one-for-one basis. To satisfy statutory tax withholding requirements, 674 of those shares were disposed of at a reference price of $426.61 per share, with the remaining net shares deposited into the holder’s account. The RSU award vests 25% per year over four years, subject to continued service. Following these transactions, Rosa directly holds 246,567 shares of Intuitive Surgical common stock.
ISRG reported a proposed sale of 665 shares of common stock. The filing lists 665 shares tied to Performance Stock Units with an effective date of 02/28/2026. The excerpt also lists prior 10b5-1 dispositions by the reporting person, including two larger blocks on 03/09/2026 for 430 shares ($208,554.30) and 215 shares ($104,277.15), and multiple smaller daily 18-share sales in May 2026.
Intuitive Surgical senior executive Iman Jeddi exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised 5,625 non-qualified stock options at $76.9989 per share and sold 5,625 common shares at $420.55 per share under a Rule 10b5-1 trading plan. After these transactions, he holds 6,463 common shares directly and 26,649 common shares indirectly through a trust.
Intuitive Surgical, Inc. has announced an internal leadership change in its commercial organization. Taylor Patton, currently Global Senior Vice President of the company’s endoluminal business, will become Chief Commercial and Marketing Officer effective July 1, 2026 and join the Executive Leadership team.
Current Chief Commercial and Marketing Officer Henry L. Charlton will transition to Senior Vice President of Global Business Operations on the same date. The company highlights Patton’s nearly two decades of experience across its da Vinci, Ion and Digital platforms and notes that Charlton will work closely with Patton to support a smooth transition in global commercial and customer-support activities.